 |
English
|
正體中文
|
简体中文
|
全文筆數/總筆數 : 29490/55136 (53%)
造訪人次 : 1993950
線上人數 : 508
|
|
|
資料載入中.....
|
請使用永久網址來引用或連結此文件:
http://ir.cmu.edu.tw/ir/handle/310903500/29053
|
| 題名: | Novel clonal der(8)t(8;14)(p11;q11),del(9)(q13q22) and t(14;22) (q13;q13) in a patient with fulminant adult T-cell leukemia/lymphoma |
| 作者: | Yeh, SP;Yu, MT;Chow, KC;Lai, LY;Chiu, CF |
| 貢獻者: | 附設醫院內科部血液腫瘤科;China Med Coll Hosp, Dept Internal Med, Div Hematol & Oncol, Taichung 404, Taiwan;China Med Coll Hosp, Dept Med Res, Canc Res Ctr, Stem Cell Res Lab, Taichung 404, Taiwan;China Med Coll Hosp, Dept Med Res, Cytogenet Lab, Taichung 404, Taiwan;China Med Coll Hosp, Dept Med Res, Canc Res Ctr, Taichung 404, Taiwan |
| 日期: | 2002 |
| 上傳時間: | 2010-09-24 14:20:00 (UTC+8) |
| 出版者: | ELSEVIER SCIENCE INC |
| 摘要: | Tissue polypeptide specific antigen (TPS) is a new tumor marker that indicates tumor proliferative rate rather than tumor burden. The purpose of this study was to assess the clinical value of TPS in patients with renal cell carcinoma (RCC). Serum levels of TPS were measured in 30 patients with locoregional and in 20 patients with advanced disease before and after therapy. The results showed that: (1) the detection sensitivity of TPS for RCC is 60.0%; (2) the detection sensitivity of TPS in advanced RCC (100.0%) was significantly higher than in locoregional RCC (33.3%); (3) the 10 locoregional RCC patients without recurrence had normal serum TPS levels during a follow-up period of 1 year; and (4) the 8 advanced RCC patients with good response during therapy had normal serum TPS levels, while 12 patients with poor disease had significantly elevated serum TPS levels during a follow-up period of 1 year. Our results suggest that TPS may have a potential clinical role as a valuable tumor marker for RCC, especially in advanced diseases and follow-up therapy response. |
| 關聯: | CANCER GENETICS AND CYTOGENETICS 139(1):34-37 |
| 顯示於類別: | [台中附設醫院] 期刊論文
|
在CMUR中所有的資料項目都受到原著作權保護.
|
